Tomasz Jaworski

List of Publications by Year
in descending order

24 papers	1,305 citations	535685 17 h-index	721071 23 g-index
25 all docs	25 docs citations	25 times ranked	2643 citing authors

#	Article	IF	Citations
1	Dysregulation of miRNAs Levels in Glycogen Synthase Kinase-3Î² Overexpressing Mice and the Role of miR-221-5p in Synaptic Function. Neuroscience, 2022, 490, 287-295.	1.1	3
2	Early synaptic deficits in GSK-3Î² overexpressing mice. Neuroscience Letters, 2022, , 136744.	1.0	2
3	Distinct circuits in rat central amygdala for defensive behaviors evoked by socially signaled imminent versus remote danger. Current Biology, 2021, 31, 2347-2358.e6.	1.8	28
4	Control of neuronal excitability by GSK-3beta: Epilepsy and beyond. Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118745.	1.9	20
5	GSK-3<i>Î²</i> at the Intersection of Neuronal Plasticity and Neurodegeneration. Neural Plasticity, 2019, 2019, 1-14.	1.0	98
6	GSK3Î² activity alleviates epileptogenesis and limits GluA1 phosphorylation. EBioMedicine, 2019, 39, 377-387.	2.7	17
7	Extracellular Matrix Modulation Is Driven by Experience-Dependent Plasticity During Stroke Recovery. Molecular Neurobiology, 2018, 55, 2196-2213.	1.9	31
8	GSK-3Î² and MMP-9 Cooperate in the Control of Dendritic Spine Morphology. Molecular Neurobiology, 2017, 54, 200-211.	1.9	43
9	The extracellular matrix glycoprotein tenascin-C and matrix metalloproteinases modify cerebellar structural plasticity by exposure to an enriched environment. Brain Structure and Function, 2017, 222, 393-415.	1.2	40
10	Terminal hypothermic <scp>T</scp>au.<scp>P</scp>301<scp>L</scp> mice have increased Tau phosphorylation independently of glycogen synthase kinase 3Î±/Î². European Journal of Neuroscience, 2014, 40, 2442-2453.	1.2	11
11	Fractalkine activates NRF2/NFE2L2 and heme oxygenase 1 to restrain tauopathy-induced microgliosis. Brain, 2014, 137, 78-91.	3.7	112
12	Early Structural and Functional Defects in Synapses and Myelinated Axons in Stratum Lacunosum Moleculare in Two Preclinical Models for Tauopathy. PLoS ONE, 2014, 9, e87605.	1.1	28
13	Neurological characterization of mice deficient in GSK3Î± highlight pleiotropic physiological functions in cognition and pathological activity as Tau kinase. Molecular Brain, 2013, 6, 27.	1.3	32
14	Tauopathy Differentially Affects Cell Adhesion Molecules in Mouse Brain: Early Down-Regulation of Nectin-3 in Stratum Lacunosum Moleculare. PLoS ONE, 2013, 8, e63589.	1.1	21
15	Structural and Functional Characterization of Nrf2 Degradation by the Glycogen Synthase Kinase 3/Î²-TrCP Axis. Molecular and Cellular Biology, 2012, 32, 3486-3499.	1.1	338
16	GSK-3Î±/Î² kinases and amyloid production in vivo. Nature, 2011, 480, E4-E5.	13.7	67
17	Dendritic Degeneration, Neurovascular Defects, and Inflammation Precede Neuronal Loss in a Mouse Model for Tau-Mediated Neurodegeneration. American Journal of Pathology, 2011, 179, 2001-2015.	1.9	105
18	GSK3 and Alzheimerâ€™s disease: facts and fictionâ€¦. Frontiers in Molecular Neuroscience, 2011, 4, 17.	1.4	128

#	Article	IF	Citations
19	Modeling of Tau-Mediated Synaptic and Neuronal Degeneration in Alzheimer's Disease. International Journal of Alzheimer's Disease, 2010, 2010, 1-10.	1.1	22
20	Alzheimer's disease: Old problem, new views from transgenic and viral models. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 808-818.	1.8	43
21	AAV-Tau Mediates Pyramidal Neurodegeneration by Cell-Cycle Re-Entry without Neurofibrillary Tangle Formation in Wild-Type Mice. PLoS ONE, 2009, 4, e7280.	1.1	71
22	Antifolate/folate-activated HGF/c-Met signalling pathways in mouse kidneysâ€"the putative role of their downstream effectors in cross-talk with androgen receptor. Archives of Biochemistry and Biophysics, 2009, 483, 111-119.	1.4	3
23	Androgen receptor and c-Myc transcription factors as putative partners in the in vivo cross-talk between androgen receptor-mediated and c-Met-mediated signalling pathways.. Acta Biochimica Polonica, 2007, 54, 253-259.	0.3	5
24	Degradation and beyond: Control of androgen receptor activity by the proteasome system. Cellular and Molecular Biology Letters, 2006, 11, 109-31.	2.7	37